Mitapivat sulfate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 573466

CAS#: 2151847-10-6 (sulfate hydrate)

Description: Mitapivat sulfate, also known as AG-348 sulfate hydrate, is an allosteric activator of Pyruvate Kinase (PK) that may be useful in the treatment of Pyruvate Kinase Deficiency.

Chemical Structure

img
Mitapivat sulfate
CAS# 2151847-10-6 (sulfate hydrate)
Instruction

Theoretical Analysis

MedKoo Cat#: 573466
Name: Mitapivat sulfate
CAS#: 2151847-10-6 (sulfate hydrate)
Chemical Formula: C48H60N8O13S3
Exact Mass: 1,052.34
Molecular Weight: 1,053.230
Elemental Analysis: C, 54.74; H, 5.74; N, 10.64; O, 19.75; S, 9.13

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 2151847-10-6 (sulfate hydrate)   1260075-17-9 (free)   2329710-91-8 (sulfate)    

Synonym: AG-348 sulfate hydrate, Mitapivat sulfate; AG-348 sulfate hydrate; AG348 sulfate hydrate;

IUPAC/Chemical Name: N-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide hemisulfate trihydrate

InChi Key: DMRIPASJCJRBMV-UHFFFAOYSA-N

InChi Code: 1S/2C24H26N4O3S.H2O4S.3H2O/c2*29-24(28-15-13-27(14-16-28)17-18-6-7-18)20-8-10-21(11-9-20)26-32(30,31)22-5-1-3-19-4-2-12-25-23(19)22;1-5(2,3)4;;;/h2*1-5,8-12,18,26H,6-7,13-17H2;(H2,1,2,3,4);3*1H2

SMILES Code: O.O.O.OS(=O)(=O)O.O=C(N1CCN(CC2CC2)CC1)c3ccc(NS(=O)(=O)c4cccc5cccnc45)cc3.O=C(N6CCN(CC7CC7)CC6)c8ccc(NS(=O)(=O)c9cccc%10cccnc9%10)cc8

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 1,053.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Yang H, Merica E, Chen Y, Cohen M, Goldwater R, Kosinski PA, Kung C, Yuan ZJ, Silverman L, Goldwasser M, Silver BA, Agresta S, Barbier AJ. Phase 1 Single- and Multiple-Ascending-Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase R, in Healthy Volunteers. Clin Pharmacol Drug Dev. 2019 Feb;8(2):246-259. doi: 10.1002/cpdd.604. Epub 2018 Aug 9. PubMed PMID: 30091852.

2: Kung C, Hixon J, Kosinski PA, Cianchetta G, Histen G, Chen Y, Hill C, Gross S, Si Y, Johnson K, DeLaBarre B, Luo Z, Gu Z, Yao G, Tang H, Fang C, Xu Y, Lv X, Biller S, Su SM, Yang H, Popovici-Muller J, Salituro F, Silverman L, Dang L. AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency. Blood. 2017 Sep 14;130(11):1347-1356. doi: 10.1182/blood-2016-11-753525. Epub 2017 Jul 31. PubMed PMID: 28760888; PubMed Central PMCID: PMC5609468.

3: Christensen RD, Yaish HM, Nussenzveig RH, Agarwal AM. Siblings with severe pyruvate kinase deficiency and a complex genotype. Am J Med Genet A. 2016 Sep;170(9):2449-52. doi: 10.1002/ajmg.a.37828. Epub 2016 Jun 29. PubMed PMID: 27354418.

4: Croasdell G. European Hematology Association - 20th Annual Congress (June 11-14, 2015 - Vienna, Austria). Drugs Today (Barc). 2015 Jul;51(7):441-5. doi: 10.1358/dot.2015.51.7.2375757. PubMed PMID: 26261846.